The Impella heart pump is a small pump that a healthcare professional can insert without surgery. It can help maintain blood flow in people who have CAD, are recovering from cardiogenic shock, or are ...

DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related ...

DANVERS, Mass.--(BUSINESS WIRE)-- The final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study demonstrate a 71% survival to discharge with greater than 90% native heart ...

PARIS--(BUSINESS WIRE)-- Abiomed (NASDAQ: ABMD) announces today that the Impella CP ® with SmartAssist technology, which is designed to improve patient outcomes with advanced algorithms and simplified ...

ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed. In more than ...

More Impella left-sided blood pumps are under Class I recall, this time for potential interactions with transcatheter aortic valve replacement (TAVR) stents, the FDA announced Thursday. The affected ...

Please provide your email address to receive an email when new articles are posted on . Abiomed is recalling specific Impella 5.5 left ventricular device systems due to product leakage. The FDA ...

TCT 69: Impella use for fulminant myocarditis in cardiogenic shock: Analysis of the Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD) Receive the the latest news, research, and ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start ...

Investigators for the DanGer trial are spreading the word on their plans to test Impella—notably, in a randomized, controlled fashion—in patients with acute MI complicated by cardiogenic shock (AMICS) ...